News Quantified

IMVT – immunovant, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Immunovant (NASDAQ:IMVT) had its "buy" rating reaffirmed by analysts at Guggenheim.

Immunovant (NASDAQ:IMVT) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $18.00 to $28.00. They now have a "neutral" rating on the stock.

Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript [Seeking Alpha]

Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement [Seeking Alpha]

Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day [Yahoo! Finance]

0.3%

MISS

-4.5%

MISS

-10.5%

MISS

-9.7%

MISS

Form 4 Immunovant, Inc. For: Dec 18 Filed by: Van Tuyl Christopher

Form SCHEDULE 13D/A Immunovant, Inc. Filed by: Roivant Sciences Ltd.

Form 4 Immunovant, Inc. For: Dec 12 Filed by: Roivant Sciences Ltd.

Form 8-K Immunovant, Inc. For: Dec 10

Form 424B5 Immunovant, Inc.

Top News Gainers

3/30 Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye Disease 23.1%

4/14 Immunovant Announces Pricing of $121.2 Million Public Offering 12.8%

12/19 Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation 12.1%

1/9 Immunovant (NASDAQ: IMVT) is now covered by analysts at Chardan Capital. They set a "buy" rating on the stock. 6.9%

2/14 Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019 6.4%

2/14 Form SC 13G/A Immunovant, Inc. Filed by: Cormorant Asset Management, LP 5.7%

4/8 Form S-1/A Immunovant, Inc. 4.3%

1/10 Immunovant (NASDAQ: IMVT) is now covered by analysts at SunTrust Banks, Inc.. They set a "buy" rating on the stock. 3.8%

3/4 Immunovant (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $27.00 price target on the stock. 3.3%

12/20 Form 4 Health Sciences Acquisit For: Dec 18 Filed by: Health Sciences Holdings, LLC 3.2%

Top News Decliners

2/12 Form SC 13G/A Immunovant, Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C. -7.3%

2/24 Immunovant (NASDAQ: IMVT) is now covered by analysts at Svb Leerink Llc. They set an "outperform" rating and a $24.00 price target on the stock. -6.0%

3/30 Form 8-K Immunovant, Inc. For: Mar 30 -6.0%

1/17 Form S-1 Immunovant, Inc. -5.5%

2/19 Form 3 Immunovant, Inc. For: Feb 18 Filed by: Venker Eric -3.8%

2/21 Immunovant (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Chardan Capital. -2.8%

2/5 Immunovant (NASDAQ: IMVT) is now covered by analysts at Nomura. They set a "buy" rating and a $27.00 price target on the stock. -2.8%

4/16 Immunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares -2.1%

2/10 Immunovant to Present at the 9th Annual SVB Leerink Global Healthcare Conference -2.0%

1/7 Immunovant (NASDAQ: IMVT) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. -1.9%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day